Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Agena Bioscience

Agena Bioscience

Agena Bioscience is a San Diego-based diagnostics company developing pharmacogenetics, liquid biopsy, and tumor profiling technologies.

Overview

Agena Bioscience was formed in 2014 when venture capital firm, Telegraph Hill Partners, acquired the Bioscience Department of Sequenom, a developer and manufacturer for the molecular diagnostic market. 

Agena Bioscience is pioneering precision medicine with its cost-effective mass spectrometry machine that has an abundance of applications in fields such as SNP genotyping, gene expression research, liquid biopsies for tumor profiling and methylation of DNA

Products

Agena Bioscience has developed various diagnostic tools and products to assist doctors and providers with providing proper care to patients.

Pharmacogenetics

When initiating treatment, healthcare providers factor in dosages, patient weight, age and even gender when prescribing the standard dosage. Clinically, however, individuals respond differently to active pharmaceutical ingredients and this is where genotyping can augment patient care. Pharmacogenetics investigates the influence of a single gene on dosing efficacy and toxicities. Analyzing genes provides an accurate pathway to optimize drug therapy and medicine metabolization.

Genetic, environmental, and developmental factors that can interact, causing variations in drug response among patients

VeriDose® Core/ CYP2D6 CNV Panel

DNA is extracted from a self-collected buccal swab which produces takes a detailed profiling of 20 different gene variants that play a factor in drug metabolism

List of gene variations detected by the MassArray VeriDose Core Panel
LIQUID BIOPSY/TUMOR PROFILING

Liquid Biopsy is a less-invasive alternative to surgical biopsies which enables physicians to obtain further information on a tumor’s progression, by drawing 5mL of a patient’s blood. While liquid biopsies have the potential to revolutionize cancer diagnosing, it is best used alongside tissue samples. 

UltraSEEK Lung, Melanoma, Colon, EFGR Panel

The genomic information retrieved determines disease progression and treatment resistance best used in molecular oncology and hematopathology.

Timeline

December 2, 2020
Agena Bioscience announces high-throughput, low-cost panel for molecular detection of SARS-CoV-2, Influenza A, and Influenza B

July 10, 2018
Agena Bioscience was founded by John Lillig.

Products

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Andrea Park
September 14, 2021
FierceBiotech
Within the first year of the buyout, Mesa said it expects Agena to bring in between $63 million and $67 million in revenue, plus an additional $3 million to $5 million in COVID testing revenue.
BioSpace
April 13, 2021
BioSpace
Ethos Laboratories®, a national leader in laboratory testing, has announced a strategic partnership with Agena® Biosciences which will leverage Agena's innovative MassARRAY MALDI-TOF platform for high throughput SARS-CoV-2 variant detection
Ethos Laboratories
April 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- Ethos Laboratories®, a national leader in laboratory testing, has announced a strategic partnership with Agena® Biosciences which will leverage...
Alliance Global (AGBL Group)
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Agena Bioscience®, the global manufacturer of the MassARRAY® System for targeted genetic analysis has signed an exclusive distribution...
Agena Bioscience
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Agena Bioscience®, the global manufacturer of the MassARRAY® System for targeted genetic analysis, today announced an exclusive distribution...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.